In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Previews (02/07)

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: Spine Devices: Looking for a Twist Rather than a Tweaks, features profiles of CoreSpine, Interventional Spine, and Paradigm Spine. Plus these Start-Ups Across Health Care: Claros Diagnostics, Cure Therapeutics, Enigma Diagnosics, Generic Medical Devices, and Nitec Pharma.

You may also be interested in...



Interventional Spine Inc.

Interventional Spine (formerly Triage Medical) hopes to push its percutaneously delivered system for both spinal fusion and dynamic stabilization.

Enigma Diagnostics Ltd.

The key to combating an infectious disease threat, be it an individual case of Chlamydia or the global threat of bioterrorism or pandemic avian flu, is rapid on-site diagnosis, enabling physicians to treat--or public health professionals to contain--the disease. One solution is the use of the gold standard test for biological agents, real-time polymerase chain reaction testing. Enigma Diagnostics Ltd. says it is the first UK company to take this technique out of the laboratory and into the field.

Generic Medical Devices Inc.

Can generics, which have had a significant impact on the pharma market, make a similar dent in the medtech world? Generic Medical Devices intends to find out. It will manufacture and sell generic versions of off-patent devices that have become the gold standard in their respective indications. Expedited regulatory, reimbursement and marketing will enable GMD to price its products at a substantial discount to their branded counterparts.

Related Content

Related Companies

UsernamePublicRestriction

Register

LL1122113

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel